Sarina A. Piha‐Paul
The University of Texas MD Anderson Cancer Center(US)
Publications by Year
Research Areas
Cancer Genomics and Diagnostics, Lung Cancer Treatments and Mutations, Cancer Immunotherapy and Biomarkers, Colorectal Cancer Treatments and Studies, HER2/EGFR in Cancer Research
Most-Cited Works
- → IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade(2017)3,762 cited
- → Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair–Deficient Cancer: Results From the Phase II KEYNOTE-158 Study(2019)2,869 cited
- → Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study(2020)2,424 cited
- → Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study(2019)1,024 cited
- → T-Cell–Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028(2018)979 cited
- → HER kinase inhibition in patients with HER2- and HER3-mutant cancers(2018)769 cited
- → Personalized Medicine in a Phase I Clinical Trials Program: The MD Anderson Cancer Center Initiative(2012)537 cited
- → Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1–Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial(2017)525 cited
- → Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE‐158 and KEYNOTE‐028 studies(2020)488 cited
- → AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer(2015)433 cited